Pazopanib Linked with Response in Pancreatic Neuroendocrine Tumors

Share this content:
Pazopanib may be associated with response in patients with pancreatic neuroendocrine tumors but not carcinoid tumors.
Pazopanib may be associated with response in patients with pancreatic neuroendocrine tumors but not carcinoid tumors.

Pazopanib may be associated with response in patients with pancreatic neuroendocrine tumors (NETs) but not carcinoid tumors, according to a recent study published online ahead of print in The Lancet Oncology.

Researchers led by Alexandria Phan, MD, and Daniel Halperin, MD, of the MD Anderson Cancer Center looked at 52 patients (32 with pancreatic NETs, 20 with carcinoid tumors) from April 2007 to July 2009 who received oral pazopanib daily with octreotide at pre-protocol dosage.

Primary endpoint was proportion of patients who achieved objective response upon intention-to-treat analysis.

They found that seven of the 32 patients with pancreatic NETs (21.9 percent) achieved an objective response, while no response in the first stage of the carcinoid tumor cohort was detected.

RELATED: Somatuline Approved by FDA for Neuroendocrine Tumors

In all patients, the most common toxic effects were fatigue, nausea, diarrhea, and hypertension.

“A randomized controlled phase 3 study to assess pazopanib in advanced NETs is warranted,” the authors concluded.

Reference

  1. Phan, Alexandria T., et al. "Pazopanib and depot octreotide in advanced, well-differentiated neuroendocrine tumours: a multicentre, single-group, phase 2 study." The Lancet Oncology. DOI: http://dx.doi.org/10.1016/S1470-2045(15)70136-1. [epub ahead of print]. May 5, 2015.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters